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osting by EAbstract To characterize the binding site of propranolol hydrochloride, the free concentration of
warfarin (site-I-speciﬁc probe) bound to BSAwas measured upon the addition of propranolol hydro-
chloride. It was found that the free concentration of warfarin sodiumwas increased from 100% (as%
of initial) to 552.35%when the ratio of propranolol to BSA was increased 1–6. In contrast, under the
same experimental conditions, when diazepamwas used as a site-II-speciﬁc probe, the increment of the
free concentration of diazepam by propranolol was from 100% (as% of initial) to 415.42. From these
data it is evident that the increment of free concentration of warfarin sodium is obviously greater than
that of diazepamby propranolol. So it can be concluded that propranolol preferentially binds to site-I.
Again as the displacement of diazepam is quite enough it can also be suggested that propranolol in
addition to site-I also binds to site-II on the BSA molecule but to a lower extent. Again in the reverse
experiment, the free concentration of propranolol was increased from 100% (as% of initial) to 476%
when warfarin to BSA ratio was 1–6 as shown, on the other hand, the free concentration of propran-
olol was increased from100%(as% initial) to 222.39%when the ratio of diazepam toBSAwas also 1–
6. From the data it is clear that the increment of propranolol due to displacement by warfarin (site-I
probe) is higher than that of propranolol when displaced by diazepam (site-II probe). Thus this reverse
experiment also agrees with the previous experiment.
ª 2009 King Saud University. All rights reserved.om (S.Md. Sharker).
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lsevier1. Introduction
The formation of a drug–protein complex is often termed
drug–protein binding. Plasma protein binding is one of the
pharmacokinetic parameters of a drug or of any compound
and takes its place along those parameters relating to absorp-
tion, distribution, biotransformation and excretion. Albumin
is the major component of plasma proteins responsible for
reversible drug or compound binding. Albumin is distributed
in the plasma and in the extracellular ﬂuids of skin, muscle
and various other tissues in the body. According to
250 A.A. Rahman, S.Md. SharkerKragh-Hansen (1981), BSA is composed of three homologous
domains. The primary structure of HSA was elucidated by
Meloun et al. (1975) and Brown (1976). It is a large multi-do-
main protein folded into three domains, each of which is built
of three loops. On the basis of probe displacement method,
there lie at least three relatively highly speciﬁc binding sites
on the BSA molecule. These sites are generally called the war-
farin-binding site, the benzodiazepine-binding site and digox-
in-binding site and are denoted as site-I, II and III,
respectively. Site-II is more speciﬁc than site-I whereas site-
III is an independent binding site (Sudlow et al., 1975, 1976).
Serum albumin, the most abundant protein in the blood, plays
a very co-important role in the binding phenomenon and
serves as a depot protein and transport protein for numerous
endogenous compounds. Displacement of drug is deﬁned as
reduction in the extent of binding of a drug to other agent,
the displacer (Kragh-Hansen, 1981). This type of interaction
may occur when two drugs or agents, capable of binding to
proteins, are administered concurrently. Competitive displace-
ment is more signiﬁcant, when two drugs or agents are capable
of binding to the same sites on the protein. From different
investigations, it has been suggested that human serum albu-
min (HSA) has limited number of binding sites. Since the num-
ber of protein binding sites is limited, competition will exist
between drugs or drugs with metals or other agents and the
agent with higher afﬁnity will displace the other and causes in-
creased free drug concentration leading to higher toxicity or
short duration of action. The ability of one drug to inhibit
the other is a function of their relative concentration, binding
afﬁnities and speciﬁcity of binding.
Nowadays propranolol is used in the treatment of hyper-
tension, angina, thyrotoxicosis as an adjuvant, supra-ventricu-
lar arrhythmias, anxiety, and phaeochromocytoma. This drug
is sometimes used with other drugs as poly-pharmacy. So
determination of binding site is important to ﬁnd out possible
side effects and to reduce side effects of combination therapy.
Thus, when studying with amitriptyline–drug interactions,
more speciﬁcally the drug displacement, the possibility of the
occurrence of site-to-site displacement should also be consid-
ered, as there will be a difference between the free concentra-
tion of a displaced drug with or without site-to-site
displacement. Moreover, protein binding property of a drug
is not a phenomenon particular to the plasma. Plasma protein
binding properties are related to plasma clearance, elimination
half-life, apparent volume of distribution and area under the
curve. BSA and HSA have structural similarity. In this study
BSA, in lieu of human (Brown, 1976) serum albumin (HSA),
was used because of its low cost and easy availability.
2. Materials and methods
Determination of binding site of propranolol HCl using warfa-
rin sodium as a site-I-speciﬁc probe or, the binding site of the
same using diazepam as a site-II-speciﬁc probe. Both experi-
ments were carried out without procedural change.
To perform the experiment the following successive steps
were followed:
(I) From the previously prepared 2 · 105 M BSA solu-
tion, 3 ml was taken into each of eight cleaned and
dried test tubes.(II) 1 · 103 M warfarin or diazepam solution was added
to seven test tubes so that the ﬁnal ratio of protein
and warfarin, or protein and diazepam was main-
tained 1:1 (2 · 105 M:2 · 105 M) in each of the
seven test tubes. The eighth test tube containing only
BSA solution was marked as ‘‘blank’’ or ‘‘Control’’.
(III) These mixtures were allowed to stand for 10 min in
order to allow binding of the warfarin to its particular
binding site (to site-I).
(IV) Propranolol HCl solution was added with increasing
concentrations into six of seven test tubes containing
1:1 mixture of protein–warfarin, or protein and diaze-
pam. The ﬁnal ratios of protein:warfarin:propranolol
HCl, or protein:diazepam:propranolol HCl were
1:1:0, 1:1:1, 1:1:2, 1:1:3, 1:1:4, 1:1:5 and 1:1:6. The test
tube no. 7 contained only protein–warfarin mixture, or
protein–diazepam mixture in the ratio 1:1.
(V) After pipetting, the solution was properly mixed and
allowed to stand for 10 min to ensure maximum bind-
ing of propranolol HCl to site-I, thereby displacing the
probe from site-I on BSA.
(VI) From each test tube 2 ml of solution was taken into
seven different semi-permeable membrane tubes. The
two ends of the membrane tube were clipped, and it
was ensured that there was no leakage.
(VII) The membrane tubes were then immersed in seven sep-
arate 50 ml conical ﬂasks containing 30 ml of phos-
phate buffer solution at pH 7.4.
(VIII) The conical ﬂasks were then placed in a metabolic sha-
ker for dialysis at 25 C and were shaken at 20 rpm.
The shaking was continued for 10 h.
(IX) At the end of the dialysis, samples were collected from
each ﬂask. The free concentrations of warfarin and
diazepam were measured by a UV spectrophotometer
at kmax = 308 and 235 nm, respectively (British Phar-
macopeia, 2000).
Determination of binding site of propranolol HCl using
warfarin sodium as a site-I-speciﬁc probe and diazepam as a
site-II-speciﬁc probe (Reverse Experiment). No procedural
change took place in both cases.
To perform the experiment the following successive steps
were followed:
(I) From the previously prepared 2 · 105 M BSA solu-
tion 3 ml was taken in each of the eight cleaned and
dried test tubes.
(II) 1 · 103 M propranolol HCl solution was added to
seven test tubes so that the ﬁnal ratio of protein and
propranolol HCl, or protein and diazepam solution
was 1:1 (2 · 105 M:2 · 105 M). The eighth test tube
containing only BSA solution was marked as ‘‘blank’’
or ‘‘Control’’.
(III) These mixtures were allowed to stand for 10 min for
allowing the binding of the propranolol HCl (to site-
I) to its particular binding site.
(IV) Warfarin sodium, or diazepam solutions (either
1 · 102 M or 1 · 103 M) were added with increasing
concentrations into six of the seven test tubes contain-
ing 1:1 mixture of protein–propranolol HCl. The ﬁnal
ratios of protein:propranolol HCl:warfarin, or pro-
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Figure 1 Free concentration of diazepam (n) and warfarin Na
() bound to BSA (1:1) upon the addition of propranolol HCl at
pH 7.4 and at 25 C. Concentration used: [BSA] = 2 · 105 M,
[warfarin] = 2 · 105 M, [diazepam] = 2 · 105 M, [proprano-
lol] = 0–12 · 105 M.
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1:1:2, 1:1:3, 1:1:4, 1:1:5 and 1:1:6. The ﬁrst test tube
contained only protein–propranolol HCl mixture
(1:1).
(V) After pipetting, the solution was properly mixed and
allowed to stand for 10 min to ensure maximum bind-
ing of warfarin sodium to site-I, or diazepam to site-II,
thereby displacing the probe from site-I in case of war-
farin sodium or displacing the probe from site-II in the
case of diazepam on BSA.
(VI) From each test tube 2 ml of solution was taken into
eight different semi-permeable membrane tubes. The
two ends of the membrane tubes were clipped, and it
was ensured that there was no leakage.
(VII) The membrane tubes were then immersed in seven sep-
arate 50 ml conical ﬂasks containing 30 ml of phos-
phate buffer solution of pH 7.4.
(VIII) The conical ﬂasks were then placed in a metabolic sha-
ker for dialysis at 25 C and were shaken at 20 rpm,
and shaking was continued for 10 h in all cases.
(IX) At the end of the dialysis, samples were collected from
each ﬂask. The free concentrations of propranolol HCl
were measured by a UV spectrophotometer at
kmax = 292 nm (British Pharmacopeia, 2000).
2.1. Drugs used in the experiment
Warfarin sodium (Incepta Pharmaceuticals Ltd., India) and
propranolol HCl (Opsonin Pharmaceuticals Ltd., India) were
the drugs used. The reagents used were disodium hydrogen
phosphate (Na2HPO4), potassium dihydrogen phosphate
(KH2PO4), borax (NaB4O7Æ10H2O) (Analytical grade, Glaxo,
UK), cellulose membrane (Medical International Ltd., Liver-
pool Road, London; mol. wt. 1200 Daltons) and Bovine Serum
Albumin (BSA) (fatty acid free, fraction V, 96–98%, mol. wt.
66,500 and it was purchased from Sigma Chemical Co., USA).
2.2. Instruments used
pH meter (HANNA Microprocessor pH Meter, Portugal),
SP8-400 UV/VIS spectrophotometer (Thermospectronic, Eng-
land), metabolic shaking incubator (Clifton Shaking Bath, Ni-
cel electro Ltd., England) and micro syringes (well. Liang. Jin.
Yang. q.I., China) were used.
2.3. Method used
Equilibrium dialysis method was employed in the study (Sin-
glas, 1987a,b).
3. Results and discussion
The complex of the drug, formed with the protein, governs
protein binding of a drug. There are two main types of
protein binding, such as strong afﬁnity binding to a small
number of sites and weak afﬁnity binding to a large
number of sites. Since binding is almost exclusively to
albumin and the number of sites available is limited, the
protein binding of some drugs depends on plasma albumin
concentration.Adequate knowledge about composition, size and location
of binding as well as probable interactions at the binding of
HSA along with all the binding of plasma protein is required
for proper explanation of pharmacokinetic aspects of drugs.
It is important for the rational understanding of drug–serum
albumin binding during concurrent administration and its met-
abolic fate during drug actions.
Propranolol HCl interactions and its binding characteristics
on BSA were studied by equilibrium dialysis method. It pro-
vided the possible way of in vitro estimates of protein binding
to propranolol HCl. The relative strength and speciﬁcity of
binding to BSA were determined by its ability to displace the
probes (warfarin as site-I-speciﬁc probe and diazepam as
site-II-speciﬁc probe) speciﬁc for particular sites site-I or site-
II on the BSA molecule (Fig. 2).
Bymeasuring the free concentration of the site-speciﬁc probe
it is inferred with regard to the binding of propranolol HCl to
BSA. In this study it was observed that the free fraction of war-
farin (site-I-speciﬁc probe) increased from100%(as%of initial)
to 552.35% with an increasing concentration from 0 to
12 · 105 M of propranolol HCl. On the other hand the free
fraction of diazepam (site-II-speciﬁc probe) increased from
100% (as % of initial) to 415% with the same increment range
of propranolol HCl (Fig. 1). That is the % increment of the free
fraction of warfarin was shown more than that of diazepam.
Again in the reverse experiment, the free concentration of
propranolol was increased from 100% (as % of initial) to
476% with an increasing concentration from 0 to
12 · 105 M of warfarin, on the other hand the free concentra-
tion of propranolol was increased from 100% (as % initial) to
222.39% with an increasing concentration from 0 to
12 · 105 M of propranolol HCl diazepam (Fig. 2). From
the data it is clear that the increment of propranolol due to dis-
placement by warfarin (site-I probe) is higher than that of pro-
pranolol when displaced by diazepam (site-II probe). Thus this
reverse experiment also agreed with the previous experiment.
So these data suggested that propranolol HCl binds
strongly to site-I (the warfarin site) than to site-II (the diaze-
pam site) on the BSA molecules. It revealed the fact that at
a lower propranolol HCl to BSA ratio, propranolol HCl binds
to site-I (high afﬁnity binding site), whereas at a high propran-
olol HCl to BSA ratio, propranolol HCl binds not only to site-
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Figure 2 Free concentration of propranolol hydrochloride when
used with diazepam (n) and warfarin Na () bound to [BSA] (1:1)
(Reverse Experiment). Concentration used: [BSA] = 2 · 105 M,
[warfarin] = 0–12 · 105 M, [diazepam] = 0–12 · 105 M, [propra-
nolol] = 2 · 105 M.
BSA
Site-I
476% release
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Warfarin Warfarin
Propranolol HCl
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Figure 4 Proposed models of the propranolol HCl binding site
to BSA, when: (C) using warfarin binding to BSA, when
[BSA] = 2 · 105 M= [propranolol HCl] and [warfarin] = 0–
12 · 105 M and (D) using diazepam binding to BSA, when
[BSA] = 2 · 105 M= [propranolol HCl] and [diazepam] = 0–
12 · 105 M (Reverse Experiment).
252 A.A. Rahman, S.Md. SharkerI (high afﬁnity binding site) but also to site-II (low afﬁnity
binding site) on BSA molecule (Figs. 3 and 4).
According to Feshke et al. (1982), the lone tryptophan res-
idue is a part of warfarin-binding site and tyrosine residues are
involved in the diazepam-binding site. He and Carter (1992)
have shown that site-I is located in sub-domain II A and in
sub-domain IIA. Site-II is more probably located in domain
III of albumin (Foster, 1977). Binding site-I is situated in do-
main II (He and Carter, 1992; Foster, 1977). Lysine and aspar-
tic acid are in the binding of drugs to site-II (Kragh-Hansen,
1981). Drugs are bound to plasma proteins at sites located
on the surface of the protein. The idea of binding sites is sug-
gested by the relative size of the drugs and proteins. Protein
binding of a drug is governed by the complex of the drug,
which forms with the protein. There are two main types of pro-
tein binding: strong afﬁnity binding to a small number of sites
and weak afﬁnity binding to a large number of sites. Since
binding is almost exclusively to albumin and the number of
sites available is limited, the protein of some drugs depends
on the plasma albumin concentration.
Here, propranolol HCl increased the free concentration of
warfarin to a greater extent than diazepam, so propranolol
HCl may probably bind with a high afﬁnity to site-I and with
a low afﬁnity to site-II in the BSA. So if people suffering from
hypertension diseases take drugs having a high afﬁnity for site-
I, it may result in a rapid action or rapid excretion from theBSA
Site-I
552.35% release
Site-II
Warfarin Warfarin
Propranolol HCl
BSA
Site-I Site-II
Propranolol HCl
415.42% release
Diazepam
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Figure 3 Proposed models of the propranolol HCl binding site
to BSA, when: (A) using warfarin binding to BSA, when [BSA] =
2 · 105 M= [warfarin] and [propranolol HCl] = 0–12 · 105 M
and (B) using diazepam binding to BSA, when [BSA] = 2 · 105
M= [diazepam] and [propranolol HCl] = 0–12 · 105 M.body or even may cause toxicity at the normal doses. This is
due to the fact that propranolol HCl has a high afﬁnity for
site-I and concurrent presence of propranolol HCl and drug
with afﬁnity for site-I. So care should be taken if a drug is pre-
scribed with propranolol HCl with site-I binding drug.Acknowledgements
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